Skip to main content
. 2020 Feb 10;12(2):406. doi: 10.3390/cancers12020406

Figure 6.

Figure 6

Ruxolitinib-persistent HEL-R cells exhibit an increased sensitivity to WP1130 or BH3 mimetics as compared with control HEL cells. (A) HEL or ruxolitinib-persistent HEL-R cells were left untreated as control or treated with 1 μM ruxolitinib for 48 h or with 2 μM WP1130 for 24 h. Viable cell numbers were measured by the CCK-8 colorimetric assay. Each column represents the mean of triplicate cultures, with error bars indicating standard errors, and is expressed as a ratio to the control. (B) HEL or HEL-R cells were treated with indicated concentrations of WP1130 for 24 h. Cells were analyzed for DNA content by flow cytometry. Percentages of apoptotic cells with the sub-G1 DNA content are indicated. (C) HEL or HEL-R cells were washed and cultured with or without 1 µM ruxolitinib for indicated times and lysed for immunoblot analysis with antibodies against indicated proteins. The results obtained from duplicate gels are shown above or below a horizontal line. ß-actin was used for a loading control. (D) HEL or HEL-R cells were treated for 3 h with indicated concentrations of WP1130 with or without 1 μM ruxolitinib, as indicated, and analyzed. HSP90 was used for a loading control. (E) HEL or HEL-R cells were left untreated as control or treated for 40 h with 1 μM ABT-737 (ABT), 5 nM A-1331852 (A-13), 1 μM ruxolitinib, or 5 μM A-1210477, as indicated, and analyzed.